Literature DB >> 8106063

Benzodiazepine use and anxiolytic abuse and dependence in treated alcoholics.

H E Ross1.   

Abstract

The prevalence and correlates of benzodiazepine use and anxiolytic abuse and dependence are examined in a sample of 427 patients in Toronto, Canada, who met lifetime DSM-III criteria for alcohol abuse or dependence. The patients were evaluated with the NIMH-DIS and other standard psychiatric and substance abuse rating scales. Forty per cent were recent users of benzodiazepines and 20% had abused or been dependent upon anxiolytics, including benzodiazepines, during their lifetime. Patients with antisocial personality disorder (ASPD) were at higher risk for an anxiolytic disorder as were women and the unemployed. Recent users of benzodiazepines showed more current psychological distress, depressive symptomatology and more severe substance abuse problems than other patients and were more likely to have a lifetime DSM-III anxiety disorder. Patients with anxiolytic disorders, even if ASPD was controlled for, showed more psychiatric impairment and drug abuse problems than the remaining patients. Of those with a positive urine screen, 46% did not report using benzodiazepines in the previous week. Nineteen per cent of the patients who did not report benzodiazepine use in the previous week had a positive urine screen and were more likely to be found in the detoxification unit.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8106063     DOI: 10.1111/j.1360-0443.1993.tb00804.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  15 in total

1.  Activation of brain NOP receptors attenuates acute and protracted alcohol withdrawal symptoms in the rat.

Authors:  Daina Economidou; Andrea Cippitelli; Serena Stopponi; Simone Braconi; Stefano Clementi; Massimo Ubaldi; Rèmi Martin-Fardon; Friedbert Weiss; Maurizio Massi; Roberto Ciccocioppo
Journal:  Alcohol Clin Exp Res       Date:  2011-01-11       Impact factor: 3.455

2.  The epidemiology of benzodiazepine misuse: A systematic review.

Authors:  Victoria R Votaw; Rachel Geyer; Maya M Rieselbach; R Kathryn McHugh
Journal:  Drug Alcohol Depend       Date:  2019-05-07       Impact factor: 4.492

Review 3.  Treatment of co-occurring anxiety disorders and substance use disorders.

Authors:  R Kathryn McHugh
Journal:  Harv Rev Psychiatry       Date:  2015 Mar-Apr       Impact factor: 3.732

4.  Benzodiazepine dependence among multidrug users in the club scene.

Authors:  Steven P Kurtz; Hilary L Surratt; Maria A Levi-Minzi; Angela Mooss
Journal:  Drug Alcohol Depend       Date:  2011-06-25       Impact factor: 4.492

5.  Twelve-step program attendance and polysubstance use: interplay of alcohol and illicit drug use.

Authors:  J Scott Tonigan; Gregory K Beatty
Journal:  J Stud Alcohol Drugs       Date:  2011-09       Impact factor: 2.582

6.  Spirituality as a change mechanism in 12-step programs: a replication, extension, and refinement.

Authors:  J Scott Tonigan; Kristina N Rynes; Barbara S McCrady
Journal:  Subst Use Misuse       Date:  2013-09       Impact factor: 2.164

7.  Measuring principal substance of abuse in comorbid patients for clinical research.

Authors:  Margaret L Griffin; Monika E Kolodziej; Roger D Weiss
Journal:  Addict Behav       Date:  2009-03-06       Impact factor: 3.913

8.  Coadministration of disulfiram and lorazepam in the treatment of alcohol dependence and co-occurring anxiety disorder: an open-label pilot study.

Authors:  Michael P Bogenschutz; Snehal Bhatt; Juliane Bohan; Bellelizabeth Foster; Paul Romo; Claire E Wilcox; J Scott Tonigan
Journal:  Am J Drug Alcohol Abuse       Date:  2016-05-16       Impact factor: 3.829

9.  Preferences for ethanol and diazepam in anxious individuals: an evaluation of the self-medication hypothesis.

Authors:  M A Chutuape; H de Wit
Journal:  Psychopharmacology (Berl)       Date:  1995-09       Impact factor: 4.530

Review 10.  Single versus multiple drug focus in substance abuse clinical trials research.

Authors:  Bruce J Rounsaville; Nancy M Petry; Kathleen M Carroll
Journal:  Drug Alcohol Depend       Date:  2003-05-21       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.